New research published in an April 2015 version of the British Medical Journal has uncovered that patients taking Xarelto are more prone to experiencing intestinal bleeding.
The study examined Xarelto versus Pradaxa and Coumadin/warfarin. It was performed by George Washington University, in conjunction with researchers at Johns Hopkins medication in Baltimore, as well as the Johns Hopkins Bloomberg School of Public Health.
The scientists examined a database of customers age 18 or older who had been prescribed these three medications from the beginning of October 2010 through the end of March 2012. The research included:
- 1,649 customers on Xarelto (rivaroxaban)
- 39,607 clients on warfarin/coumadin
- 46,163 patients on Pradaxa (dabigatran)
Notably, there is a somewhat smaller number of people prescribed Xarelto in this study pool due to the fact that it was authorized by the U.S. Food And Drug Administration (FDA) in July 2011 — mid-way through the timeframe for this research study.
The 2015 Xarelto Study Findings
Despite the fairly small number of study participants on Xarelto, the results were clear: patients on Xarelto had a 200 percent higher risk of intestinal bleeding when compared to those on warfarin/coumadin.
Notably, Pradaxa — also considered a “new generation” blood thinner medicine — shares the increased threat of gastrointestinal bleeding; the danger was 50 percent greater than Warfarin/Coumadin (yet it was 4x lower when compared to the bleeding risk for Xarelto).
It must be mentioned that Pradaxa doesn’t have an antidote, but the blood thinner’s impact can be reversed via dialysis.
Xarelto reversal is not possible through dialysis and there’s no Xarelto antidote available. Patients who experience complications and interior bleeding from Xarelto must wait until the drug normally simply leaves theirsystem. The Xarelto half life in a healthier person age 20-45 is 5 to 9 hours; it can be significantly longer in a less-than-healthy person.
The conclusions for this 2015 Xarelto research aren’t isolated. A 2012 study called “Rocket AF” disclosed an increased occurrence of abdominal (GI) hemorrhaging situations when Xarelto vs. coumadin was examined.
Xarelto Lawsuits: MDL Court Situations Continue
You can find hundreds of Xarelto lawsuits continuing in federal court, as clients look for compensation for health problem that arose due to Xarelto bleeding, side effects and other problems stemming from the blood thinner medicine.
The attorneys with the Meldofsky Law Firm are now taking on new clients who’ve experienced severe Xarelto side effects, like uncontrolled intestinal bleeding and other complications. State regulations do impose a limitation on how long you have to file a lawsuit against Xarelto, so it is vital that you take action immediately.
Contact The Meldofsky Law Firm for a completely private and no-cost consultation regarding your case. Call 877-274-8672.